# To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

> **NCT03707535** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 270 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** CT-P13
- **BIOLOGICAL:** Remicade

## Key facts

- **NCT ID:** NCT03707535
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-12
- **Primary completion:** 2020-03-16
- **Final completion:** 2021-03-05
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2021-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03707535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03707535, "To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03707535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*